![]()
|
|
||||||||
(Received for publication, June 2, 1997, and in revised form, July 30, 1997)
From the It has been suggested that the cardiac slow
delayed rectifier channel is formed by the association of two subunits:
IsK (also called minK) and KvLQT1. N-terminal splice variants of the
human KvLQT1 gene have been identified, but the functional roles of different KvLQT1 isoforms are not clear. Using the nested 5 KvLQT1 was first identified as a gene involved in the long-QT
syndrome by positional cloning (1). Hydropathy analysis revealed a
structure of six putative transmembrane The linkage between KvLQT1 mutations and abnormal QT prolongation in
long-QT patients clearly indicates the importance of KvLQT1 subunits
(and thus IKs channels) in action potential repolarization in the heart
(1, 5-7). KvLQT1 and IsK are coexpressed not only in heart but also in
other organs (e.g. inner ear (6) and kidney and pancreas (2,
8)). Therefore, they may form IKs channels that serve a variety of
physiological functions in different organs.
It has been shown that there are alternative splice variants in the
5 In the present study, we applied the
5 The technique of rapid amplification of
5
The
cDNAs of tKvLQT1, KvLQT1 (2), hIsK (10), Kv1.4 (11), Kv4.3 (12),
and hERG (13) were transcribed using a commercial kit (mMessage
mMachine, Ambion, TX) and appropriate RNA polymerases. The cRNA
products of the transcription reactions were quantified by denaturing
RNA gel electrophoresis against known quantities of RNA size markers
(Life Technologies, Inc.). Oocytes were prepared and injected with cRNA
solutions as described previously (11). For cRNA coinjections, the
concentrations of cRNA stock solutions were adjusted and mixed so that
each oocyte would receive 40 or 50 nl of a solution containing the
desired amounts of cRNAs. The amounts of cRNAs injected will be
specified in the figure legend or text.
Whole-cell currents were
recorded using the two-microelectrode voltage clamp technique. The
current-passing and voltage-recording electrodes were made of
"agar-cushion" pipettes (14) of tip resistance 0.1-0.3 M We designed a PCR primer pair specific for the
tKvLQT1 isoform by using a program, Primer Select, from DNA Star. The
primer sequences (M and N) are denoted in Fig. 1. A PCR primer pair
specific for the full-length human heart KvLQT1 isoform was reproduced from a previous study (LQT201 and LQT301 (9)). Tissues were dissected
from different regions of a nonfailing human heart. Poly(A) RNA was
prepared from the tissue samples using a commercial kit (Poly(A) Pure,
Ambion). These poly(A) RNAs and two independent lots of normal human
heart poly(A) RNA from CLONTECH (Lot numbers 56719 and 6080159) were subject to RT-PCR reactions using a commercial kit
(PE Express Ampli-Taq RT-PCR kit). For each reverse
transcription, 0.25 µg of poly(A) RNA was used in a 20-µl reaction
mix, and a combination of oligo(dT) and random hexamer primers was used
for the initiation of cDNA synthesis. For negative controls, the
reactions were run in the absence of reverse transcriptase. Each of the 20-µl cDNA product was divided into two halves and subjected to PCR amplification using the primer pair specific for tKvLQT1 or for
KvLQT1. PCR protocol was 30 cycles of 94 °C/30 s, 60 °C/45 s, and
72 °C/45 s, with a 94 °C/5 min hot start in the beginning of the
cycles and a 72 °C/7 min extension at the end. The PCR products were
size-fractionated by electrophoresis on a 2% gel of 3:1 (w/w)
agarose:synergel (Diversified Biotech).
Fig.
1 illustrates the nucleotide sequence of
the 5 The full-length KvLQT1
encodes a voltage-gated potassium channel in oocytes with properties
similar to those described by other investigators (2-4). On the other
hand, tKvLQT1 expressed alone at a 10-fold higher amount of cRNA
(n = 30) did not give any currents similar to those
recorded from KvLQT1-expressing oocytes. There are two possible
explanations for these results. First, tKvLQT1 could be folded
correctly in the cell membrane, but did not have channel function.
Alternatively, tKvLQT1 might not be folded correctly and thus was
degraded inside the cell, i.e. tKvLQT1 did not generate
functional proteins. By analogy to other voltage-gated potassium
channels (15), a functional KvLQT1 channel should be formed by a
tetramer of the subunits. Therefore, if tKvLQT1 generated correctly
folded proteins that could be assembled with the full-length isoform,
it might interfere with the KvLQT1 channel function. This was tested by
coexpressing tKvLQT1 and KvLQT1 in oocytes at a cRNA ratio of 10:1 (30 ng of tKvLQT1 plus 3 ng of KvLQT1). As shown in Fig.
2A, in all 12 oocytes examined
that had been coinjected with tKvLQT1 and KvLQT1, no KvLQT1 current
could be detected. On the other hand, a robust KvLQT1 current was
consistently observed in another 12 oocytes isolated from the same frog
and received an equal amount of full-length KvLQT1 cRNA but without
tKvLQT1.
These observations indicate that tKvLQT1 could generate correctly
folded proteins in oocytes. These truncated subunits could coassemble
with the full-length KvLQT1 subunits and suppressed channel function.
These results further suggest that the cytoplasmic N terminus and the
initial S1 domain of the KvLQT1 subunit are not essential for subunit
coassembly. Therefore, the structural domains involved in subunit
coassembly in KvLQT1 appear to be different from those in channels of
other Kv gene families (16). This is also suggested by the lack of a
sequence "EYFFDR" in the N terminus of KvLQT1. This sequence is
conserved in potassium channels of Kv1 to Kv4 subfamilies and is found
in the N-terminal domains that are crucial for subfamily-specific
subunit coassembly (16).
In some uninjected oocytes, we could resolve a small,
time-dependent outward current (Fig. 2A). This
current appeared to be similar to that induced by the full-length human
KvLQT1 in showing a mild inward rectification upon strong
depolarization (data not shown). Therefore, it might originate from the
KvLQT1 isoform endogenous to Xenopus oocytes (2). At +40 mV,
this time-dependent outward current amounted to 0.13 ± 0.01 µA on day 1 after oocyte isolation (n = 5),
and 0.09 ± 0.01 µA on day 2 (n = 10). These current amplitudes are significantly larger than those seen in oocytes
coinjected with tKvLQT1 and KvLQT1 (at +40 mV, 0.06 ± 0.004 µA
on day 1, p < 0.05, and 0.02 ± 0.007 µA on day
2, p < 0.001). Therefore, tKvLQT1 disrupted the
channel function of not only the exogenously expressed full-length
human KvLQT1, but also the endogenous Xenopus KvLQT1.
When hIsK was expressed in oocytes, it induced an IKs
current similar to the cardiac IKs (Fig. 2B). It has been
suggested that hIsK subunit coassembles with the endogenous
Xenopus KvLQT1 subunit to form functional IKs channels (2).
When coexpressing tKvLQT1 with hIsK at a cRNA ratio of 10:1 (30 ng of
tKvLQT1 plus 3 ng of hIsK), the amplitude of IKs was consistently and
significantly reduced (Fig. 2B). The
time-dependent current during a 5-s depolarization pulse to
+40 mV was 2.39 ± 0.18 µA in oocytes injected with hIsk alone
(n = 10), but only 0.66 ± 0.06 µA in oocytes
injected with hIsK along with tKvLQT1 (n = 12, p < 0.001). These data suggest that tKvLQT1 could
suppress the function of IKs channels induced by hIsK, probably by
competing with endogenous Xenopus KvLQT1 subunits in
coassembly with the hIsK subunits.
There remain two questions regarding the
"specificity" of tKvLQT1's effects on channel expression. First,
in the experiments shown in Fig. 2, 30 ng of tKvLQT1 cRNA was
coinjected with 3 ng of KvLQT1 or hIsK cRNA. Could such an amount of
tKvLQT1 cRNA saturate the protein translation machinery of oocytes,
causing a nonspecific reduction of expression of other channel
subunits? Second, are the suppressing effects of tKvLQT1 specific for
KvLQT1 and IKs, or can it suppress the expression of other seemingly
unrelated potassium channel subunits? These two questions are addressed in the experiments shown in Fig. 3.
Coinjection of tKvLQT1 with KvLQT1 at a cRNA ratio of 4:1 (8 ng of
tKvLQT1 plus 2 ng of KvLQT1) reduced the KvLQT1 current amplitude by
81 ± 3% (p < 0.001). In oocytes injected with 2 ng of KvLQT1 plus 0.2 ng of hIsK, coinjection of 8 ng of tKvLQT1
reduced the IKs current amplitude by 56 ± 7% (p < 0.001). On the other hand, increasing the amount of KvLQT1 cRNA
injected from 2 to 10 ng (equal or similar to the total amounts of
cRNAs received by the tKvLQT1-coinjected oocytes) augmented the current
amplitude by 226 ± 43%, suggesting that 8 ng of tKvLQT1 cRNA
probably did not saturate the translation machinery. The same amount of
tKvLQT1 (8 ng) did not significantly affect the expression of Kv1.4,
Kv4.3, or hERG (induced by 2 ng of channel cRNA, p
We used the RT-PCR technique to see if the two KvLQT1
isoforms can be detected in the same anatomical regions of human heart. KvLQT1- and tKvLQT1-specific PCR primer pairs were used to amplify the
respective isoform sequences from mRNAs isolated from four different regions of a nonfailing human heart. As shown in Fig. 4, both isoform-specific bands were
detected in the left and right atria and the left and right ventricular
epicardium. Fig. 4 also shows that both isoform specific bands were
detected from two independent CLONTECH mRNA
preparations from normal human heart. It is important to note that
these results are similar to two recent reports, both of which show
that human heart is unique among many human tissues in coexpressing the
full-length and the truncated KvLQT1 isoforms (3, 9). This, in
conjunction with data presented in Fig. 3, indicates that the
suppressing effect of tKvLQT1 on channel function is likely to be
specific for IKs in the heart.
Since the tKvLQT1 isoform was cloned from and identified in normal
human hearts, the observations we report here (i.e.
coexpression of tKvLQT1 with full-length KvLQT1 in different regions of
the human heart and a suppressing effect of tKvLQT1 on the function of
the slow delayed rectifier channel) are of physiological significance. Coexpression of tKvLQT1 with KvLQT1 in cardiac myocytes at different ratios may be one contributing factor to the observed regional heterogeneity in the IKs current amplitude in the heart (19). It has
been suggested that, under the influence of drugs or pathological conditions, regions of the ventricle that have a low IKs current density tend to develop abnormally prolonged action potentials and may
form the foci of arrhythmogenesis due to early or delayed afterdepolarizations (20). Therefore, it is important to pinpoint the
cellular distribution of tKvLQT1 versus KvLQT1 in the heart and to correlate this expression pattern with the IKs current density.
We thank Drs. Thomas Colatsky, Randal Numann,
and Philip Babij for helpful comments on this manuscript.
Volume 272, Number 39,
Issue of September 26, 1997
pp. 24109-24112
©1997 by The American Society for Biochemistry and Molecular Biology, Inc.
COMMUNICATION:
,
¶
Department of Pharmacology, Columbia
University, New York, New York 10032 and the § Wyeth-Ayerst
Research, CN 8000, Princeton, New Jersey 08543-8000
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES
-rapid amplification of cDNA ends technique, we obtained a truncated isoform of KvLQT1 (termed tKvLQT1) that lacks the N-terminal
cytoplasmic domain and the initial one-third of the first transmembrane
domain. The function of tKvLQT1 was tested by oocyte expression, alone or together with the full-length KvLQT1 or a human IsK clone (hIsK). tKvLQT1 alone did not generate functional channels. However, it suppressed the KvLQT1 current when coexpressed with the full-length isoform. It also suppressed the slow delayed rectifier current induced
by hIsK, probably by competing with the KvLQT1 subunit endogenous to
Xenopus oocytes in coassembly with the hIsK subunit. On the
other hand, tKvLQT1 did not suppress the expression of Kv1.4, Kv4.3, or
hERG. Using the reverse transcription-polymerase chain reaction
technique, we further show that the truncated and full-length isoforms
are coexpressed in different regions of human heart. Therefore, tKvLQT1
may modulate the function of IKs in human cardiac myocytes.
-helices and a "pore" region homologous to those of known potassium channels. Subsequently, KvLQT1 was cloned from human (2, 3) and other species (mouse (4),
Xenopus oocytes (2)). The full-length KvLQT1 encodes a
potassium channel whose properties do not resemble those of any
potassium channel described for cardiac myocytes (2-4). However, when
coexpressed with IsK (also called minK) in mammalian cells, a potassium
channel with properties similar to those of cardiac slow delayed
rectifier (IKs) channel is produced (2, 4). These results suggest that
KvLQT1 subunits probably do not form homomultimer channels in the
heart, but are associated with IsK subunits to form functional IKs
channels. Expressing IsK alone in oocytes can induce an IKs current,
because oocytes have an endogenous KvLQT1 subunit (2). Coexpression of
exogenous KvLQT1 with IsK in oocytes greatly increases the amplitude of
IKs, probably by augmenting the KvLQT1 protein level in the oocytes
(2-4).
-end of the human KvLQT1 gene (9). Therefore, there may be KvLQT1
isoforms that have different gating properties or serve various
functions. However, the roles of splice variants of KvLQT1 proteins
have not been examined.
-RACE1 technique to amplify
the 5
-end sequences of KvLQT1 from a CLONTECH
cDNA preparation made from normal human hearts. A sequence was
obtained that represents a truncated isoform of KvLQT1 (tKvLQT1). We
characterized the function of tKvLQT1 by expressing it alone in oocytes
or together with the full-length KvLQT1 isoform, a human IsK subunit,
or several unrelated potassium channel subunits (Kv1.4, Kv4.3, and
hERG). Furthermore, the distribution of the truncated and full-length KvLQT1 isoforms in different regions of human heart was examined by the
RT-PCR technique.
Cloning of tKvLQT1
-complementary DNA ends (5
-RACE) was used to amplify KvLQT1
N-terminal sequences from cDNAs of normal human hearts
(CLONTECH Marathon Ready cDNA, Lot number
6050943). Two 5
-RACE primers were synthesized based on the partial
KvLQT1 cDNA sequence (GeneBank accession number U40990 (1)). Primer
A corresponds to nucleotides 427 to 401 of U40990:
5
-CAGGAAGCCGATGTACAGGGTGGTTA-3
. Primer B corresponds to nucleotides
351-326 of U40990: 5
-CCTCCCTGGCGGTCGACGTGTAGCAT-3
(denoted in Fig.
1). These two primers were combined with CLONTECH RACE adapter primers for two sequential nested PCR amplifications (30 cycles of 95 °C/30 s, 70 °C/1 min, and 72 °C/1 min, beginning with hot start and ending with an additional 72 °C/7 min extension). PCR products were fractionated on 1% agarose gel. One major band of
approximately 650 bp was consistently seen in multiple PCR reactions.
This band was purified and cloned into a TA-cloning vector (pCR2.1,
Invitrogen). Six of the 5
-RACE clones were sequenced for both strands.
They have the same sequence except minor variations in the 5
-ends
(denoted by open circles in Fig. 1). Two of the 5
-RACE
clones were selected for transfer of the 5
differentially spliced exon
into the human KvLQT1 cDNA clone (a gift of Dr. M. T. Keating
(2)), using a unique restriction enzyme site, NgoMI, that is
shared between the 5
-RACE clones and the KvLQT1 clone. The complete
construct, termed tKvLQT1, was subcloned into a vector, pcDNA3(+)
(Invitrogen), for expression and functional analysis. DNA sequencing
was carried out by an ABI373 automated DNA sequencer and the
dye-termination method. Computer software used for DNA sequence
analysis included Sequencher (GeneCodes), Lasergene (DNA Star), BLAST
(National Center for Biotechnology Information), and Genetics Computer
Group (University of Wisconsin).
Fig. 1.
Nucleotide sequence of the 5
-RACE clone and
the deduced amino acid sequence of tKvLQT1. The sequences of
primer B used in the second run of 5
-RACE reaction (see
"Experimental Procedures") and the primer pair, M and N, used in
the RT-PCR reactions (see Fig. 4) are indicated by lines
with arrows indicating the forward or reverse direction. The
three open circles in the 5
-region indicate the starts of
5
-ends of six 5
-RACE clones sequenced. Putative transmembrane
-helices from S1 (truncated in tKvLQT1) to S6 and the pore region
are highlighted by a gray background. The splice
junction is marked by a downward triangle (9).
[View Larger Version of this Image (59K GIF file)]
. To
decrease the interference from endogenous chloride currents, we used a
low-chloride bath solution of the following composition (in
mM): NaOH, 96; MgSO4, 1; CaCl2,
1.8; KOH, 2; sodium pyruvate, 2.5; HEPES, 5 (pH titrated to 7.5 with methanesulfonic acid). An oocyte clamp (model OC-725C, Warner Instrument Corp., Hamden, CT) was used for voltage clamping. Protocol generation and data acquisition were controlled by Clampex of pClamp
(version 5.5, Axon Instruments, Foster City, CA). Currents were
low-pass-filtered at 2 kHz (Frequency Devices, Harverhill, MA) and
digitized for off-line analysis. Data analysis was performed using
Clampfit of pClamp (version 6.1). Data are presented as means and S.E.
where appropriate. Statistical analysis was carried out using
SigmaStat (version 2, Jandel Scientific). After determining that
there were significant differences among multiple groups of data using
one-way analysis of variance, pairwise comparisons were performed using
unpaired t test or Mann-Whitney rank sum test.
Cloning of a Truncated Isoform of KvLQT1 (tKvLQT1)
-RACE clone we obtained from normal human heart cDNA. The
351-bp sequence from the 3
-end of the RACE clone is identical to the
KvLQT1 cDNA sequence (1). The remaining 5
-end sequence is
completely different from that of KvLQT1 (5), but is identical to the
available sequence of a differentially spliced KvLQT1 exon (1b)
recently identified in the human KvLQT1 gene (9). Therefore, with
5
-RACE, we cloned an N-terminal splice variant of KvLQT1. The deduced amino acid sequence indicates that this KvLQT1 isoform is shorter than
the full-length isoform by 127 amino acids (lacking the cytoplasmic N
terminus and the initial part of the first transmembrane domain, S1)
(Fig. 1). Therefore, we call this truncated isoform "tKvLQT1." In
the following experiments testing the functional role of tKvLQT1, cRNAs
from three independent clones were used, and the results were the same.
Therefore the data were pooled.
Fig. 2.
A, tKvLQT1 coexpression suppressed the
KvLQT1 current. Upper, current traces recorded from an
oocyte injected with 3 ng of KvLQT1 alone (left) or 3 ng of
KvLQT1 plus 30 ng of tKvLQT1 (middle) and an uninjected
oocyte (right). The currents were activated by 1-s
depolarization pulses from a holding voltage
(Vh) of
80 mV to test voltages
(Vt) of
50 to +60 mV in 10-mV increments at an
interval of 15 s. The depolarization pulses were followed by
repolarization to
60 mV for 1 s to monitor the tail current. Lower, summary data of effects of tKvLQT1 coexpression on
the function of KvLQT1 channels in oocytes. Time-dependent
currents developed during the 1-s depolarization pulses are plotted
against Vt. Shown are mean values (symbols) and
S.E. bars. When the bars are not seen, they are smaller than the
symbols. Numbers in parentheses denote the
numbers of experiments. B, tKvLQT1 coexpression suppressed the slow delayed rectifier current induced by hIsK in oocytes. Upper, current traces recorded from an oocyte injected with
3 ng of hIsK alone (left) or coinjected with 3 ng of hIsK
plus 30 ng of tKvLQT1 (right). The currents were activated
by 5-s depolarization pulses from Vh
50 to
Vt
30 to +60 mV in 10-mV increments once every
30 s. The depolarization pulses were followed by a 5-s step to
40 mV to monitor the tail current. Lower, summary data of effects of tKvLQT1 coexpression on IKs function induced by hIsK in
oocytes. Time-dependent currents developed during 5-s
depolarization pulses are plotted against Vt.
Amounts of cRNAs injected in the experiments included in the summary
data were the same as those described for the representative
experiments in the upper panels.
[View Larger Version of this Image (22K GIF file)]
0.2). Therefore, tKvLQT1 reduced KvLQT1 or IKs current amplitude not by
a nonspecific effect of reducing subunit translation and was not seen
with three other potassium channel subunits. The lack of effects of
tKvLQT1 coexpression on Kv4.3 and hERG function is significant, because
these two subunits are important for the transient outward and rapid
delayed rectifier currents in the human heart, respectively (17,
18).
Fig. 3.
Specificity of suppression of channel
function by tKvLQT1 coexpression. Shown are normalized current
amplitudes plotted against the types of cRNAs injected. Each oocyte
received 2 ng of cRNA of KvLQT1, Kv1.4, Kv4.3, or hERG or 2 ng of
KvLQT1 plus 0.2 ng of hIsK (hIsK + KvLQT1), without
(white bars) or with (black bars) 8 ng of
tKvLQT1. Another batch of oocytes received 10 ng of KvLQT1 cRNA each
(gray bar). The current amplitude was measured as current
level 1 s after depolarization to +60 mV (KvLQT1), peak
current at +60 mV (Kv1.4 and Kv4.3), peak tail
current at
60 mV after a 1-s depolarization pulse to +60 mV
(hERG) or time-dependent current during a 5-s
depolarization pulse to +40 mV (hIsK + KvLQT1). For each
channel type, the current amplitudes were normalized by the mean
current amplitude recorded from oocytes not receiving tKvLQT1 cRNA. For
oocytes receiving 10 ng of KvLQT1, the current amplitudes were
normalized by the mean current amplitude recorded from oocytes injected
with 2 ng of KvLQT1. Recordings were made 36-60 h after injection.
Similar results were obtained using oocytes from two frogs, and the
data were combined (n = number of oocytes tested). *,
p < 0.001 by unpaired t test between
current amplitudes from oocytes without or with tKvLQT1 coinjection or
between oocytes receiving 2 or 10 ng of KvLQT1.
[View Larger Version of this Image (27K GIF file)]
Fig. 4.
Coexpression of tKvLQT1 and KvLQT1 in human
heart revealed by RT-PCR reactions. Tissues from the following
regions of a nonfailing human heart were used for poly(A) RNA
preparation: left and right atrial appendages (LA and
RA), epicardium from left and right ventricles
(LV(Epi) and RV(Epi)). "Heart 1"
and "heart 2" are two independent lots of normal human
heart poly(A) RNA from CLONTECH. Reverse
transcription reactions were run in the absence (
RT, as
negative control) or presence (+RT) of reverse transcriptase. For each of the poly(A) RNA samples, products from the
two RT-PCR reactions with tKvLQT1- and KvLQT1-specific primer pairs
were combined for electrophoresis. The lanes marked by
"tKvLQT1" and "KvLQT1" are products from
parallel PCR reactions using plasmid DNAs of the tKvLQT1 and KvLQT1
clones as PCR DNA templates. They serve to illustrate the specific
sizes produced from the two isoforms (tKvLQT1, 298 bp; KvLQT1, 348 bp).
[View Larger Version of this Image (27K GIF file)]
*
This work was supported in part by Grants HL46451 (to
G. N. T.) and HL30557 (to G. N. T.) from the NHLBI,
National Institutes of Health, Bethesda, MD.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
¶
To whom correspondence should be addressed: Dept. of
Pharmacology, Columbia University, 630 West 168th St., New York, NY
10032. Tel.: 212-305-4166; Fax: 212-305-8780; E-mail
gt10{at}columbia.edu.
1
The abbreviations used are: RACE, rapid
amplification of cDNA ends; RT-PCR, reverse
transcription-polymerase chain reaction; bp, base pair(s).
©1997 by The American Society for Biochemistry and Molecular Biology, Inc.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
B. L. vanTol, S. Missan, J. Crack, S. Moser, W. H. Baldridge, P. Linsdell, and E. A. Cowley Contribution of KCNQ1 to the regulatory volume decrease in the human mammary epithelial cell line MCF-7 Am J Physiol Cell Physiol, September 1, 2007; 293(3): C1010 - C1019. [Abstract] [Full Text] [PDF] |
||||
![]() |
X.-S. Liu, M. Jiang, M. Zhang, D. Tang, H. F. Clemo, R. S. D. Higgins, and G.-N. Tseng Electrical remodeling in a canine model of ischemic cardiomyopathy Am J Physiol Heart Circ Physiol, January 1, 2007; 292(1): H560 - H571. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Nerbonne and R. S. Kass Molecular Physiology of Cardiac Repolarization Physiol Rev, October 1, 2005; 85(4): 1205 - 1253. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Thomas, A.-B. Wimmer, C. A. Karle, M. Licka, M. Alter, M. Khalil, H. E. Ulmer, S. Kathofer, J. Kiehn, H. A. Katus, et al. Dominant-negative IKs suppression by KCNQ1-{Delta}F339 potassium channels linked to Romano-Ward syndrome Cardiovasc Res, August 15, 2005; 67(3): 487 - 497. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Kolski-Andreaco, H. Tomita, V. G. Shakkottai, G. A. Gutman, M. D. Cahalan, J. J. Gargus, and K. G. Chandy SK3-1C, a Dominant-negative Suppressor of SKCa and IKCa Channels J. Biol. Chem., February 20, 2004; 279(8): 6893 - 6904. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. T. Kurata, G. S. Soon, J. R. Eldstrom, G. W. K. Lu, D. F. Steele, and D. Fedida Amino-terminal Determinants of U-type Inactivation of Voltage-gated K+ Channels J. Biol. Chem., August 2, 2002; 277(32): 29045 - 29053. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. R. Finley, Y. Li, F. Hua, J. Lillich, K. E. Mitchell, S. Ganta, R. F. Gilmour Jr., and L. C. Freeman Expression and coassociation of ERG1, KCNQ1, and KCNE1 potassium channel proteins in horse heart Am J Physiol Heart Circ Physiol, July 1, 2002; 283(1): H126 - H138. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. F Bosch and S. Nattel Cellular electrophysiology of atrial fibrillation Cardiovasc Res, May 1, 2002; 54(2): 259 - 269. [Full Text] [PDF] |
||||
![]() |
S. Demolombe, G. Lande, F. Charpentier, M. A van Roon, M. J.B van den Hoff, G. Toumaniantz, I. Baro, G. Guihard, N. Le Berre, A. Corbier, et al. Transgenic mice overexpressing human KvLQT1 dominant-negative isoform Part I: Phenotypic characterisation Cardiovasc Res, May 1, 2001; 50(2): 314 - 327. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Pereon, S. Demolombe, I. Baro, E. Drouin, F. Charpentier, and D. Escande Differential expression of KvLQT1 isoforms across the human ventricular wall Am J Physiol Heart Circ Physiol, June 1, 2000; 278(6): H1908 - H1915. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Chouabe, N. Neyroud, P. Richard, I. Denjoy, B. Hainque, G. Romey, M.-D. Drici, P. Guicheney, and J. Barhanin Novel mutations in KvLQT1 that affect Iks activation through interactions with Isk Cardiovasc Res, March 1, 2000; 45(4): 971 - 980. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. M. Roden and S. Kupershmidt From genes to channels: normal mechanisms Cardiovasc Res, May 1, 1999; 42(2): 318 - 326. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Plata, D. B. Mount, V. Rubio, S. C. Hebert, and G. Gamba Isoforms of the Na-K-2Cl cotransporter in murine TAL II. Functional characterization and activation by cAMP Am J Physiol Renal Physiol, March 1, 1999; 276(3): F359 - F366. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Neyroud, P. Richard, N. Vignier, C. Donger, I. Denjoy, L. Demay, M. Shkolnikova, R. Pesce, P. Chevalier, B. Hainque, et al. Genomic Organization of the KCNQ1 K+ Channel Gene and Identification of C-Terminal Mutations in the Long-QT Syndrome Circ. Res., February 19, 1999; 84(3): 290 - 297. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Demolombe, I. Baro, Y. Pereon, J. Bliek, R. Mohammad-Panah, H. Pollard, S. Morid, M. Mannens, A. Wilde, J. Barhanin, et al. A Dominant Negative Isoform of the Long QT Syndrome 1 Gene Product J. Biol. Chem., March 20, 1998; 273(12): 6837 - 6843. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |